Early circulating biomarker signatures of dengue-associated plasma leakage uncovered by proteomics

Samaneh Moallemi[1,2], Anne Poljak[1,3], Nicodemus Tedla[1], Chathurani Sigera[4], Praveen Weeratunga[4], Deepika Fernando[4], Senaka Rajapakse[4], Andrew Lloyd[2], Chaturaka Rodrigo[1,2*]

[1]School of Biomedical Sciences, Faculty of Medicine, UNSW Sydney, NSW, 2052, Australia
[2]Viral Immunology Systems Program, Kirby Institute, UNSW Sydney, NSW, 2052, Australia
[3]Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, UNSW Sydney, NSW, 2052, Australia
[4]Faculty of Medicine, University of Colombo, 25, Kynsey Road, CO008, Colombo, Sri Lanka

*Corresponding author: c.rodrigo@unsw.edu.au, +61 2 9065 2186

Addresses of the authors

Author 1, Author 2, Author 3, Author 8, Author 9: Faculty of Medicine and Health, Wallace Wurth Building (C27), Cnr High St & Botany St, UNSW, Kensington NSW 2052.

Author 4, Author 5, Author 6, Author 7: Faculty of Medicine, University of Colombo, 25, Kynsey Road, Colombo 08, 00800, Sri Lanka

Preferred degree:

Author 1: PhD candidate

Author 2, Author 3, Author 4, Author 6, Author 9: PhD

Author 5, Author 7, Author 8: MD

Abstract

Background: Plasma leakage, a defining feature of severe dengue, lacks early predictive biomarkers critical for timely clinical decision-making. We aimed to characterize early proteomic signatures of dengue-associated plasma leakage using two complementary high-throughput platforms.

Methods: Febrile-phase plasma samples were collected from 222 dengue patients (stratified by plasma leakage and prior dengue exposure), 50 febrile non-dengue controls, and 6 healthy individuals. Proteomic profiling of pooled plasma was performed using liquid chromatography–tandem mass spectrometry (LC-MS/MS) and SomaScan aptamer-based platforms. Differential expression, pathway enrichment, and protein–protein interaction analyses were conducted to identify leakage-associated signatures.

Findings: We identified 23 proteins differentially expressed and validated across both platforms, and 108 (LC-MS/MS) and 3181 (SomaScan) proteins identified as differentially expressed by at least one platform, in patients who subsequently developed plasma leakage. Prior dengue exposure shaped the molecular response with secondary infections exhibiting multi-system inflammatory responses with metabolic dysregulation and immune signalling pathways. Network analysis revealed greater protein connectivity and more complex interaction clusters involving multiple biological pathways compared to primary infections.

Interpretation: This proteomic screening identified candidate biomarkers that merit validation in other cohorts to assess generalisability. Such validated biomarkers could be useful in predicting plasma leakage and hence triaging patients for hospital admission in future.

Funding: National Health and Medical Research Council of Australia (1173666); University of Colombo, Sri Lanka (AP/3/2/2017/CG/25).

Research in context

Evidence before this study

Plasma leakage is a defining feature of severe dengue and the earliest objective indicator of clinical deterioration. Early identification of patients at risk of leakage could improve triage and reduce complications, particularly in resource-limited settings. However, most studies to date have used composite outcomes such as severe dengue or dengue haemorrhagic fever, which are subject to more inter-observer bias. Our prior systematic review found limited high-certainty evidence for plasma leakage-specific predictive biomarkers. In follow-up experimental work guided by the systematic review, we identified proteins—such as VCAM-1, IL-33R, and CCL11—independently associated with plasma leakage. However, a comprehensive, untargeted proteomic screen could identify more predictive proteins for plasma leakage. Most previous proteomic studies used a single platform, focused on general dengue severity rather than vascular-specific outcomes, and did not stratify by infection history—despite secondary infection being an established risk factor for adverse outcomes. The extreme dynamic range of the plasma proteome, spanning over ten orders of magnitude, necessitates complementary high-throughput approaches for robust biomarker discovery.

Added value of this study

This is the first study to use two complementary high-throughput proteomics platforms—mass spectrometry and aptamer-based analysis—to identify early host protein signatures predictive of dengue-associated plasma leakage. We analysed febrile-phase plasma from a well-characterised prospective cohort with predefined clinical endpoints and stratification by prior dengue exposure. We identified 23 proteins consistently differentially expressed across both platforms. These included novel markers of metabolic stress, endothelial dysfunction, and liver-derived proteins. Network and pathway analyses further revealed distinct regulatory architectures in primary versus secondary dengue infections and identified topologically central proteins with high translational relevance.

Implications of all the available evidence

This study reframes plasma leakage in dengue as a clinically actionable, multi-system process involving immune, metabolic, and endothelial disruption, with dominant hepatic involvement. The 23 cross-validated biomarkers offer a practical foundation for developing early risk stratification tools to guide triage and monitoring decisions during the febrile phase—when patients still appear clinically stable but are at risk of rapid deterioration.

Introduction

Plasma leakage is a defining pathophysiological hallmark of severe dengue posing substantial challenges in clinical management but only seen in 35-38% of patients [1]. While not all patients with plasma leakage develop shock or organ failure, nearly all severe dengue cases exhibit plasma leakage, making it a biologically determined, clinically actionable and objectively measurable intermediate outcome[2]. In contrast to the broader WHO severity classifications like severe dengue and dengue haemorrhagic fever—which are composite clinical criteria often inconsistently applied[3]—plasma leakage is a single criterion can be defined through more objective parameters, such as change in haematocrit or imaging evidence of fluid accumulation[1].

Currently, the risk of plasma leakage cannot be predicted during the “early” febrile phase of dengue[4], when decisions regarding hospital admission and monitoring must be made. This uncertainty contributes to both unnecessary hospitalisations and missed opportunities for timely intervention—particularly in resource-limited settings where seasonal surges strain clinical capacity[5]. The timing of plasma leakage, typically following peak viraemia, supports a model in which host immune responses—rather than direct viral cytopathy—drive endothelial dysfunction. This is especially evident in secondary infections, where antibody-dependent enhancement amplifies immune activation and contributes to vascular inflammation[6].

A very few proteomic studies[7-15], along with several targeted investigations measuring individual proteins, have implicated mechanisms such as cytokine release, glycocalyx degradation, and endothelial activation in plasma leakage. However, these findings remain fragmentary and not specific to plasma leakage, and relied on a single proteomics platform without cross-validation.

To improve understanding of the early host responses preceding plasma leakage, we conducted what is, to our knowledge, the first study to apply a high-throughput, dual-platform proteomic strategy. By integrating complementary technologies, we aimed to achieve broad and sensitive proteome coverage across key biological pathways implicated in

vascular dysfunction and identify predictive biomarkers for plasma leakage, a critical knowledge gap in dengue.

Methods

Cohort characteristics and clinical assessment

Plasma and clinical data were obtained from the Colombo Dengue Study (CDS), a prospective observational cohort conducted between the University of Colombo, Sri Lanka, and University of New South Wales, Australia. Participants with suspected dengue were recruited between 2017-2020 at the National Hospital of Sri Lanka within 96 hours of fever onset, according to WHO clinical case definition. Comprehensive CDS methodology has been published previously[16].

Dengue infection was confirmed by bedside detection of non-structural protein 1 (NS1) antigen (SD Bioline, Alere SD, USA) and RT-qPCR (SuperScript III Platinum One-Step Quantitative RT-PCR System, Invitrogen, USA). Infection status (primary vs. secondary) was determined by anti-dengue envelope IgG assay (Euroimmun, Germany), with IgG presence indicating prior infection. Clinical management was provided per local guidelines, independent of molecular results.

Participants underwent daily clinical evaluation. Plasma leakage was defined by standardised criteria: ≥20% haematocrit elevation from baseline, absolute haematocrit ≥45%, or ultrasonographic evidence of third-space fluid accumulation (pleural effusions or ascites). No participants exhibited plasma leakage at sampling.

Ethical approvals were granted by the University of Colombo (EC/17/080), UNSW Sydney (HC220706), and St Vincent's Hospital Sydney (for healthy controls) (HREC/13/SVH/145). Written informed consent was obtained from all participants.

Study design

A total of 222 dengue plasma samples, 50 non-dengue febrile controls, and 6 healthy controls were included. Dengue samples were stratified into four clinical categories: primary dengue without plasma leakage (PD+PL-), primary dengue with plasma leakage (PD+PL+), secondary dengue without plasma leakage (PD-PL-), and secondary dengue with plasma leakage (PD-PL+) with the latter subdivided into severe (SD) and non-severe cases. Age- and sex-matched pools were generated with 50 individuals per pool, except severe dengue (22 patients). 6 healthy controls were volunteers with Sri Lankan ancestry volunteers recruited in Australia. All participants were free of comorbidities likely to confound the proteomic analysis.

Plasma proteomic analyses

Two complementary proteomic platforms were used: liquid chromatography–tandem mass spectrometry (LC-MS/MS) and SomaScan aptamer-based proteomic profiling. LC-MS/MS analysis was performed with high-abundance protein depletion and technical duplicates. SomaScan aptamer-based analysis targeting ~11,000 proteins was performed by SomaLogic Inc. with adaptive normalization by maximum likelihood. Further details of proteomics workflow, and computational analysis are provided in the Supplementary Materials.

Statistical analysis

For data from both platforms, differential expression analysis was conducted using the limma package (R version 4.2.2), applying linear modelling and empirical Bayes moderation. Presence-absence filtering was used to retain proteins consistently detected across all

biological samples within each group. Log2-transformation, technical replicate correlation, sample quality weighting, and robust variance modelling were applied.

The group comparisons included: plasma leakage versus no leakage (across all dengue cases, irrespective of infection history); primary dengue with leakage (PD+PL+) versus without leakage (PD+PL-); secondary dengue with leakage (PD-PL+) versus without leakage (PD-PL-); severe (SD; presenting with either compensated or uncompensated shock) versus non-severe dengue; and secondary dengue patients who progressed to severe dengue versus those who did not. Additional comparisons were also made against non-dengue febrile (ND) and healthy controls (HC) (Figure 1).

For LC-MS/MS data, proteins with a log□ fold change ≥1 and $p \leq 0.05$ were considered significantly differentially expressed; For SomaScan, a threshold of log□ fold change ≥0.2 and $p \leq 0.05$ was applied. As previously recommended[17], this more permissive threshold improves sensitivity given the nonlinear signal response of some SOMAmers at high protein concentrations. Spearman correlation was used to assess concordance between platforms. Statistical analyses and visualizations were performed using R (v4.2.2) using built-in functions and the packages limma, ggplot2, and corrplot.

Proteins consistently regulated across both platforms were prioritized as the most robust biomarker candidates, noting that differentially expressed proteins may also be detected by one platform alone, given that they are not similar, but rather complementary methods.

Pathway and network analysis

Significantly altered proteins were subjected to functional and network analysis using Metascape v3.5[18]. The Molecular Complex Detection (MCODE) algorithm was applied to identify densely connected modules. Protein–protein interaction networks were then constructed using STRING v12.0 (minimum interaction score: 0.4) and visualised in Cytoscape v3.10.3. To enhance mechanistic insight, proteins with log□ fold change ≥1 and $p \leq 0.05$ from either LC-MS/MS or SomaScan were included in pathway and network analyses, leveraging the complementary coverage of both platforms. The Human Protein Atlas was consulted to assess tissue-specific expression and subcellular localisation, supporting the biological relevance of candidate biomarkers in plasma leakage. Further details are provided in the Supplementary Material, and a schematic overview of the study design, samples and analytical workflow is provided in Figure 2.

Role of funders

Funders had no role in study design, data analyses, interpretation, or writing.

Results

We analysed plasma samples from 222 dengue patients stratified by plasma leakage status, infection history (primary vs secondary), and disease severity[3], along with 50 non-dengue febrile controls and 6 healthy individuals of Sri Lankan ancestry (Table 1). To ensure comprehensive proteome coverage, two high-throughput platforms were used: liquid chromatography–tandem mass spectrometry (LC-MS/MS) and aptamer-based proteomics (SomaScan). In total, 1,358 proteins were detected by LC-MS/MS (Table S3) and 9,665 unique protein targets by SomaScan (Table S4), after collapsing multiple measurements per protein across all groups. Of these, 910 proteins were detected by both platforms (Table S5). Technical reproducibility metrics for both methods are presented in the Supplementary Data (Figures S1,S3,S4).

Table 1. Participant characteristics by study groups

Group	N	Mean Age (years)	Male (%)
Primary dengue			
Without plasma leakage (PD+PL−)	50	29.34	80.0
With plasma leakage (PD+PL+)	50	27.82	78.0
Secondary dengue			
Without plasma leakage (PD-PL−)	50	35.5	50.0
With plasma leakage (PD-PL+)	50	36.6	48.0
Severe dengue (SD)	22	26.04	68.2
Controls			
Non-dengue febrile	50	35.1	50.0
Healthy controls	6	34.0	66.7

Proteome signatures associated with dengue associated plasma leakage

In the main analysis (Comparison 1 in Figure 1), to identify early changes of the plasma proteome associated with plasma leakage, we compared febrile-phase plasma from patients who subsequently developed leakage (PL+) with those who did not (PL–), without stratifying by prior dengue exposure. LC-MS/MS analysis revealed 108 differentially expressed proteins (DEPs) using differential expression (log□ fold change ≥1, p≤0·05) and presence/absence analyses, with 88 upregulated and 20 downregulated in PL+ patients (Figure 3A, Table S6), including 7 proteins detected exclusively in PL+ samples and 2 exclusively in PL– samples (Figure 3C). SomaScan profiling identified 3,181 DEPs (log□ fold change ≥0·2, p≤0·05), comprising 1,634 upregulated and 1,547 downregulated proteins in PL+ patients (Figure 3B, Table S7). Between-platform comparisons revealed that 23 DEPs were identified by both platforms and hence cross validated as early biomarkers of plasma leakage (Table 2).

Table 2. The 23 biomarkers associated with plasma leakage in dengue cross validated between both proteome analysis platforms

Uniprot ID	Gene Symbol	Description	Direction of change in patients with plasma leakage
Q12906	ILF3	Interleukin enhancer-binding factor 3	Upregulated
P62805	H4C1	Histone H4	Upregulated
O43175	PHGDH	D-3-phosphoglycerate dehydrogenase	Upregulated
P40763	STAT3	Signal transducer and activator of transcription 3	Upregulated
Q00266	MAT1A	S-adenosylmethionine synthase isoform type-1	Upregulated
P05161	ISG15	Ubiquitin-like protein ISG15	Upregulated
P00167	CYB5A	Cytochrome b5	Upregulated
Q13046	PSG7	Pregnancy-specific beta-1-glycoprotein 7	Upregulated
P31327	CPS1	Carbamoyl-phosphate synthase [ammonia], mitochondrial	Upregulated
Q8N4T8	CBR4	3-oxoacyl-[acyl-carrier-protein] reductase	Upregulated
Q14117	DPYS	Dihydropyrimidinase	Upregulated
Q9UQ80	PA2G4	Proliferation-associated protein 2G4	Upregulated
P10124	SRGN	Serglycin	Upregulated
P08238	HSP90AB1	Heat shock protein HSP 90-beta	Upregulated
Q9UL46	PSME2	Proteasome activator complex subunit 2	Upregulated
P02461	COL3A1	Collagen alpha-1(III) chain	Upregulated
P42224	STAT1	Signal transducer and activator of transcription 1-alpha/beta	Upregulated
Q96S86	HAPLN3	Hyaluronan and proteoglycan link protein 3	Upregulated
P62249	RPS16	40S ribosomal protein S16	Upregulated
Q00887	PSG9	Pregnancy-specific beta-1-glycoprotein 9	Upregulated
P25815	S100P	Protein S100-P	Downregulated
P21291	CSRP1	Cysteine and glycine-rich protein 1	Downregulated
Q9NQ38	SPINK5	Serine protease inhibitor Kazal-type 5	Downregulated

For a comprehensive systems-level analysis, differentially expressed proteins from both platforms (including those detected by one platform only) were integrated using stringent

criteria (log□FC ≥ 1, p ≤ 0.05), resulting in 199 upregulated and 203 downregulated proteins for pathway enrichment and protein-protein interaction (PPI) network analyses. Upregulated proteins in the plasma leakage group were enriched in several key biological processes, including carboxylic acid metabolism (q = 1.1×10□¹¹), cellular catabolism (q = 8.3×10□□), PI3K-Akt signalling (q = 5.5×10□□), haemostasis (q = 6.8×10□□), cytokine signalling (q = 4.2×10□□), JAK-STAT signalling (q = 9.1×10□□), and neutrophil degranulation (q = 3.9×10□□) (Figure 4A, Table S8). Downregulated proteins were enriched in positive regulation of protein modification (q = 0.0085), apoptotic signalling (q = 0.012), astrocyte development (q = 0.012), and adaptive immunity (q = 0.012) (Figure 4B, Table S10).

To further explore how DEPs function in relation to one another (connectivity and functional relationships), protein-protein interaction (PPI) network analysis was performed. This analysis revealed several densely interconnected modules, suggesting coordinated biological activity within subnetworks. Notably MCODE modules (a method for clustering highly connected regions of a network) were enriched for proteasome function (p = 3.2×10□¹□), stress responses (p = 7.9×10□□), and JAK-STAT signalling (p = 1.3×10□¹□) (Figure 5A, Table S9). PPI analysis of downregulated proteins identified modules associated with protein kinase regulation (p = 2.0×10□□), antimicrobial defence (p = 1.6×10□¹¹), and ECM-receptor interactions (p = 2.5×10□□) (Figure 5B, Table S11).

Complementing the modular analysis, topological analysis was performed to investigate the regulatory structure of the network. This approach identified proteins that occupied key positions in the network based on graph theory metrics[19]. Proteins with high degree centrality—or many connections—were considered hubs, often playing integrative or regulatory roles. In this network, IL6 (degree = 56), HSP90AA1 (55), and CTNNB1 (50) were identified as major hubs, indicating their central role in coordinating multiple pathways relevant to inflammation, stress, and cellular signalling. In contrast, bottleneck proteins were identified based on high betweenness centrality, indicating that they lie on many of the shortest paths between other proteins and may mediate communication between distinct modules. Bottlenecks with moderate connectivity but high betweenness centrality included ITIH1 (9.21×10□□), TLR6 (8.41×10□□), and LAMC1 (5.58×10□□), bridging modules related to protease inhibition, immune signalling, and basement membrane structure. Identifying hubs and bottlenecks provided insight into both core regulatory drivers and key inter-module connectors, of the molecular architecture underlying plasma leakage.

Collectively, these findings highlight a divergence between upregulated pathways related to inflammation, metabolism, and coagulation, and downregulated pathways involved in tissue remodelling, immune regulation, and cell death, in plasma leakage (Figure 6, Tables 3 and S12).

Table 3. Top 20 Hub Proteins Identified by Network Analysis (Dengue with plasma leakage vs. without plasma leakage)

Rank	Protein	Degree	Betweenness	Percentile	Betweenness Category	Functional Category
1	IL6	56	0.12636	99.5%	Very High (>95%)	Inflammatory/Immune
2	HSP90AA1	55	0.13417	99.7%	Very High (>95%)	Chaperone/Stress Response
3	CTNNB1	50	0.10919	99.2%	Very High (>95%)	Cell Adhesion/Wnt Signalling
4	MYC	47	0.10202	99.0%	Very High (>95%)	Transcription/Cell Cycle
5	HSP90AB1	47	0.08649	98.5%	Very High (>95%)	Chaperone/Stress Response
6	STAT3	39	0.06297	98.5%	Very High (>95%)	Transcription/Signal Transduction

7	IL10	31	0.02486	94.6%	High (90-95%)	Inflammatory/Immune
8	ACO2	30	0.04699	97.9%	Very High (>95%)	Metabolism/TCA Cycle
9	FGF2	28	0.02045	91.8%	High (90-95%)	Growth Factor/Angiogenesis
10	STAT1	27	0.02363	93.6%	High (90-95%)	Transcription/Signal Transduction
11	SNCA	25	0.04038	96.6%	Very High (>95%)	Neurological/Synapse
12	GPI	24	0.04152	96.9%	Very High (>95%)	Metabolism/Glycolysis
13	B2M	24	0.03668	95.4%	Very High (>95%)	Immune/MHC
14	BRCA1	24	0.02442	94.3%	High (90-95%)	DNA Repair/Cell Cycle
15	ITGB3	23	0.05478	97.9%	Very High (>95%)	Cell Adhesion/Migration
16	RPS16	23	0.03712	95.6%	Very High (>95%)	Ribosomal/Translation
17	PSMA7	22	0.01203	85.3%	Medium-High (75-90%)	Proteasome/Protein Degradation
18	CALML3	22	0.0418	97.4%	Very High (>95%)	Calcium Signalling
19	CCN2	22	0.02086	92.0%	High (90-95%)	Growth Factor/ECM
20	PDGFRA	21	0.03906	96.3%	Very High (>95%)	Growth Factor Receptor/Signalling

All 20 proteins were classified as global hubs (nodes with high connectivity across multiple network modules, in contrast to local hubs which are highly connected within a single module), including key inflammatory (IL6, IL10), stress response (HSP90AA1, HSP90AB1), and transcriptional regulators (STAT3, MYC). Proteins involved in cell adhesion and vascular regulation, such as CTNNB1 and ITGB3, were also prominent.

Plasma leakage signatures stratified by infection history

To assess influence of prior dengue exposure, which is an established risk factor for plasma leakage, we repeated the above analysis stratified by prior dengue exposure. In primary dengue (Comparison 2 in Figure 1), 100 DEPs were identified by LC-MS/MS (64 up-, 36 down-regulated) (Table S13) while 3,445 DEPs were identified using SomaScan (1,937 up-, 1,508 down-regulated) (Table S14), with 10 protein changes consistently identified across both platforms (Table S15). In secondary dengue (Comparison 3 in Figure 1), 160 DEPs were identified by LC-MS/MS (130 up-, 30 down-regulated)(Table S16) and 2,424 DEPs were identified using SomaScan (1,090 up-, 1,334 down-regulated) (Table S17), with 24 protein changes consistently identified across both platforms (Table S18).

Primary infection was associated with upregulation of glycolytic processes ($q=6.9\times10^{\square\square}$), ECM interactions ($q=2.0\times10^{\square\square}$), and neutrophil degranulation ($q=4.7\times10^{\square\square}$) (Figure S5A, Table S19). PPI analysis revealed modules centred on proteasomal activity ($p=7.9\times10^{\square 11}$) and JAK-STAT signalling ($p=1.6\times10^{\square\square}$)(Table S20). Downregulated proteins were associated with growth factor responses ($q=1.7\times10^{\square 3}$) and cellular migration ($q=0.020$) (Figures S5B,Table S21).

Secondary infection exhibited more intense metabolic and inflammatory signatures, with upregulation of carboxylic acid metabolism ($q=6.8\times10^{\square 1\square}$), neutrophil functions ($q=1.2\times10^{\square\square}$), and uniquely, systemic autoimmunity ($q=6.9\times10^{\square\square}$) and neutrophil extracellular trap (NET) formation ($q=1.1\times10^{\square\square}$) (Figure S6A, Table S22). PPI analysis revealed modules linked to lupus pathways ($p=4.0\times10^{\square 1\square}$), histone deacetylation ($p=1.6\times10^{\square 1\square}$), and antigen presentation ($p=2.0\times10^{\square 1\square}$) (Table S23). Downregulated pathways included protein modification ($q=2.3\times10^{\square\square}$), apoptotic regulation ($q=3.5\times10^{\square\square}$), and VEGF signalling ($q=4.9\times10^{\square\square}$) (Figure S6B, Table S24), with PPI networks centred on protein modification ($p=1.3\times10^{\square 1\square}$), apoptotic signalling ($p=6.3\times10^{\square 1\square}$), and proteolysis regulation ($p=3.2\times10^{\square\square}$) (Table S25). .

Topological analysis showed that primary dengue networks featured hubs like STAT3 and IL10 (Table S26), while secondary dengue was dominated by IL6 and CTNNB1, with greater connectivity (mean hub degree: 48.0 vs. 29.4) (Table S27).

Discussion

This proteomic characterisation of early biomarker signatures associated with plasma leakage in dengue infection leveraged two orthogonal platforms—mass spectrometry and aptamer-based proteomics—to identify 23 consistently differentially expressed and cross-validated proteins when unadjusted for prior dengue exposure.

The unadjusted plasma leakage proteome also revealed coordinated disruption of immune, metabolic, and endothelial pathways. Among the 20 upregulated proteins, key signalling mediators such as STAT1[20], STAT3[20],ISG15[21], and HSP90AB1[22] highlight early activation of cytokine and stress response pathways, while the presence of PSME2[23] suggests heightened proteasomal activity. Extracellular HISTONE H4, linked to neutrophil extracellular traps (NETs), may support emerging evidence of NET involvement in dengue vasculopathy[24]. Notably, although extracellular matrix proteins COL3A1, HAPLN3 [25,26] have been previously linked to dengue, several metabolic regulators identified here—CPS1, a liver-derived urea cycle enzyme promoting anti-inflammatory M2 macrophage polarisation, MAT1A, which regulates methionine metabolism and interferon-mediated antiviral responses, and PHGDH, a serine biosynthesis enzyme modulating antiviral innate immunity—have not previously been linked to dengue and represent novel candidates for further investigation. These findings align with pathway-level enrichment for catabolism, proteostasis, and anti-inflammatory signalling, including IL-10-associated pathways, suggesting a metabolic reprogramming towards limiting immune activation and increased energy (ATP) production.

Several proteins upregulated in the plasma leakage group have been previously implicated in dengue pathogenesis, though not all in the context of severe disease. STAT1 and STAT3 were among the most prominent, previously identified as central regulators in transcriptomic studies of dengue shock syndrome (DSS) via IFN and NF-κB signaling[20]. STAT3 also promotes viral replication in vitro, and its inhibition reduces dengue virus protein expression[27]. HSP90AB1, another upregulated protein, facilitates dengue virus entry via lipid rafts in monocytes and epithelial cells, though its role in severe clinical outcomes remains unclear[22]. COL3A1, an extracellular matrix protein, has been associated with immune modulation and vascular remodelling in dengue, including via interactions with endogenous retroviral elements linked to increased endothelial permeability[25]. HAPLN3, which facilitates extracellular matrix binding and matrix stabilization, was previously noted in dengue pathophysiology[28]. In contrast, S100P, which was downregulated in our plasma leakage group, has previously been reported as upregulated in DSS[20], suggesting context-dependent expression based on disease severity. While most prior studies focused on general dengue infection or early immune responses, our findings place these proteins within the specific context of plasma leakage, a critical knowledge gap in the field.

Early downregulation of S100P, SPINK5, and CSRP1, all involved in vascular tone and cytoskeletal dynamics, may indicate impaired endothelial homeostasis in patients who subsequently develop leakage. Suppression of kinase signalling, protein modification, and adaptive immune pathways further support a model of selective immune dampening. Notably, we observed opposing regulation within endothelial pathways: upregulation of vascular wall and haemostatic pathways, but downregulation of ECM-receptor interactions and focal adhesion proteins, implying spatially distinct and partial disruption of endothelial barrier integrity.

Together, these findings support a model in which plasma leakage is driven by early metabolic and inflammatory remodelling, accompanied by selective disruption of endothelial structure and function. Key protein biomarkers—such as STAT3, HSP90AB1, COL3A1, PHGDH, and HIST1H4A—offer mechanistic insight and represent promising candidates for early detection and therapeutic targeting of vascular leakage in dengue. Notably, 15 of the 23 cross-validated proteins are highly expressed in the liver. Building on previous work identifying liver-derived biomarkers such as CRP and AST as early predictors of severe outcome[29], this analysis further expands the list of hepato-centric biomarkers associated with adverse dengue outcomes.

In addition to differential expression, network topology analysis provided insights into the regulatory architecture of plasma leakage. Two distinct classes of proteins with complementary roles were identified. Hub proteins, such as IL6, STAT3, CTNNB1, and HSP90AA1, exhibited extensive connectivity and likely act as master regulators coordinating inflammatory, stress response, and cell adhesion pathways. In parallel, bottleneck proteins—including TLR6, LAMC1, and ITIH1—were characterised by high betweenness centrality despite modest connectivity, suggesting they function as critical gatekeepers linking immune signalling, extracellular matrix integrity, and vascular regulation networks. These contrasting topological roles imply that hubs may broadly activate key pathways, while bottlenecks may control specific, rate-limiting steps in vascular dysfunction. From a translational perspective, while hubs are central to disease networks, they may lack diagnostic specificity due to involvement in multiple biological processes and functional redundancy. Bottlenecks, by contrast, may offer greater specificity, as their perturbation is more likely to reflect targeted pathway disruption with minimal confounding. Therapeutically, bottlenecks may also be more tractable, as their modulation could influence key interactions with fewer systemic effects than targeting hubs. Thus, by integrating network topology with expression data, we identified proteins that are not only differentially regulated but also potentially positioned to influence disease progression.

Stratified analysis adjusted for prior dengue exposure provides a more refined view of the pathophysiology of plasma leakage. In patients with primary dengue and plasma leakage, we observed upregulation of glycolysis-related proteins (e.g., ENO1, PKM), extracellular matrix (ECM) interaction pathways, and proteasome components, consistent with a coordinated stress and remodelling response to initial viral exposure. In contrast, plasma leakage in secondary dengue was associated with pronounced early metabolic dysregulation—particularly in amino acid and lipid metabolism—alongside intensified inflammatory signalling and autoimmune-like features, consistent with antibody-dependent enhancement and heightened immunopathology. While both infection types shared signatures of metabolic adaptation and innate immune activation, secondary dengue exhibited broader proteomic shifts involving inflammatory amplification, loss of immune regulation, and pathways linked to vascular destabilisation.

Network topology further highlighted these differences: secondary dengue showed greater hub connectivity, dominated by inflammatory mediators such as IL6, STAT3, and HSP90AA1. This inflammatory-centric network architecture offers a molecular rationale for the more severe clinical manifestations often seen in secondary infection and suggests that these shifts may occur early, even before clinical divergence becomes apparent. Whereas primary infection appears to induce adaptive metabolic and proteostatic responses, secondary infection overrides regulatory controls, leading to amplified immune activation and greater risk of tissue damage.

Our findings advance prior proteomic studies of dengue, which have typically focused on general infection markers rather than leakage-specific signatures[7-15]. For example, Choudhury et al[12]. highlighted broad inflammatory and endothelial alterations; however, did not stratify by plasma leakage status, limiting insights into the molecular events underlying vascular dysfunction. In contrast, the 23-cross-platform consistent proteins identified in our study represent a distinct signature, with only six (STAT1[20], STAT3[20,27], HSP90AB1[22], COL3A1[25], HAPLN3[28], and S100P[20]) overlapping with prior dengue datasets. Of these, four (STAT1, STAT3, S100P, and COL3A1) have been previously associated with severe outcome through mechanisms involving interferon signalling, immune dysregulation, or vascular permeability[20,25,27]. The remaining proteins, therefore, represent novel candidates previously unlinked to adverse outcomes in dengue.

These findings have important clinical implications. As in most resource limited settings prior dengue exposure is not tested for and self-report is unreliable[30] the comparison of all patients with and without plasma leakage is more relevant to on the ground clinical risk stratification. The 23 cross-validated DEPs between these two groups should be prioritised for further development and testing (e.g., independent quantitative validation in a second cohort) towards the aim of developing a point-of-care diagnostics for early risk prediction. Moreover, several proteins—particularly HSP90AB1, STAT1, and STAT3—have existing inhibitors that could be explored in ex-vivo or animal models, if their roles in plasma leakage are confirmed. However, when the analysis is unadjusted for prior dengue exposure, the results observed in CDS which is dominated by a people with prior dengue exposure may not be generalisable to children, travellers from non-endemic regions, and people in newly endemic areas where primary infections will dominate. The molecular signatures from the adjusted analysis (stratified by prior dengue exposure) must be considered in such instances.

This body of work had several other limitations also. Pooling of samples may have masked inter-individual variability, particularly for low-abundance proteins. The sampling window, restricted to the first 96 hours of illness, was treated as a homogeneous phase, but daily or hourly fluctuations in protein expression may have been missed due to the lack of serial sampling. Although the dual-platform design enhanced discovery power and confidence, the limited overlap between platforms reflects inherent differences in their sensitivities and target range. Furthermore, given the semi-quantitative output, this study is best described as a high throughput screening effort and the top DEPs for each comparison should be quantitatively validated in independent cohorts and functionally assessed in ex vivo or animal models to confirm their predictive utility.

In conclusion, this study presented a comprehensive dual-platform proteomic screen that identified novel circulating biomarkers potentially predictive of dengue-associated plasma leakage. The findings revealed extensive crosstalk between immune, metabolic, and structural pathways, reframing plasma leakage as a multi-system process with dominant hepatic involvement—rather than solely an immune-mediated event. Prioritising these biomarkers for future validation may improve early risk stratification and support the development of point-of-care diagnostics and targeted therapies for dengue.

Contributors

Concept and design: SM, CR, AL, AP, NT

Sample and data collection: CS, PW, DF, SR

Funding acquisition: CR, DF, AL

Experiments: SM, AP

Data analysis: SM

Interpretation of results: SM, CR, AL, AP, NT

Supervision: CR, AL, AP, NT

Writing – original draft: SM

Writing – review & editing: all authors

Final approval: all authors

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data sharing

Processed proteomic data supporting the findings of this study are provided in the supplementary Excel file available at Harvard Dataverse: https://doi.org/10.7910/DVN/HKHVSN. Requests for additional data access should be directed to the corresponding author and will be considered on a case-by-case basis following appropriate ethical and institutional approvals.

References

1. Moallemi S, Tedla N, Sigera C, et al. Early circulating biomarkers to predict plasma leakage in dengue fever. *Journal of Infection* 2025: 106401.
2. Srikiatkhachorn A. Plasma leakage in dengue haemorrhagic fever. *Thrombosis and haemostasis* 2009; **102**(12): 1042-9.
3. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control: World Health Organization; 2009.
4. Rodrigo C, Sigera C, Fernando D, Rajapakse S. Plasma leakage in dengue: a systematic review of prospective observational studies. *BMC infectious diseases* 2021; **21**: 1-11.
5. John DV, Lin Y-S, Perng GC. Biomarkers of severe dengue disease–a review. *Journal of biomedical science* 2015; **22**: 1-7.
6. Guzman MG, Vazquez S. The complexity of antibody-dependent enhancement of dengue virus infection. *Viruses* 2010; **2**(12): 2649.
7. Kumar Y, Liang C, Bo Z, Rajapakse JC, Ooi EE, Tannenbaum SR. Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. *PLoS Neglected Tropical Diseases* 2012; **6**(11): e1887.
8. Balasubramanian S, Janakiraman L, Kumar SS, Muralinath S, Shivbalan S. A reappraisal of the criteria to diagnose plasma leakage in dengue hemorrhagic fever. *Indian pediatrics* 2006; **43**(4): 334.
9. Nhi DM, Huy NT, Ohyama K, et al. A proteomic approach identifies candidate early biomarkers to predict severe dengue in children. *PLoS neglected tropical diseases* 2016; **10**(2): e0004435.
10. Han L, Ao X, Lin S, et al. Quantitative comparative proteomics reveal biomarkers for dengue disease severity. *Frontiers in Microbiology* 2019; **10**: 2836.
11. Jadhav M, Nayak M, Kumar S, et al. Clinical proteomics and cytokine profiling for dengue fever disease severity biomarkers. *Omics: a journal of integrative biology* 2017; **21**(11): 665-77.
12. Choudhury KR, Verma P, Ray AG, et al. Differential Proteomic Profiling at Different Phases of Dengue Infection: An Intricate Insight from Proteins to Pathogenesis. *Journal of Proteome Research* 2024; **23**(9): 3731-45.
13. Brasier AR, Garcia J, Wiktorowicz JE, et al. Discovery proteomics and nonparametric modeling pipeline in the development of a candidate biomarker panel for dengue hemorrhagic fever. *Clinical and translational science* 2012; **5**(1): 8-20.
14. Panwar A, Goel R, Kumar R, et al. Identification and validation of plasma proteins associating with severe dengue by quantitative proteomics and biochemical approaches. *International Journal of Infectious Diseases* 2020; **101**: 234.
15. Allgoewer K, Maity S, Zhao A, et al. New proteomic signatures to distinguish between Zika and Dengue infections. *Molecular & Cellular Proteomics* 2021; **20**.
16. Sigera C, Rodrigo C, de Silva NL, Weeratunga P, Fernando D, Rajapakse S. Direct costs of managing in-ward dengue patients in Sri Lanka: A prospective study. *PloS one* 2021; **16**(10): e0258388.
17. Candia J, Cheung F, Kotliarov Y, et al. Assessment of Variability in the SOMAscan Assay. *Scientific Reports* 2017; **7**(1): 14248.
18. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nature Communications* 2019; **10**(1): 1523.
19. Barabási A-L, Oltvai ZN. Network biology: understanding the cell's functional organization. *Nature Reviews Genetics* 2004; **5**(2): 101-13.
20. Hoang LT, Lynn DJ, Henn M, et al. The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. *J Virol* 2010; **84**(24): 12982-94.
21. Shaabani N, Zak J, Johnson JL, et al. Accumulated ISG15 Drives Immune Pathology and Respiratory Failure During Systemic Viral Infection. *Available at SSRN 3784881*.

22. Reyes-del Valle J, Chávez-Salinas S, Medina F, Del Angel RM. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. *Journal of virology* 2005; **79**(8): 4557-67.
23. Wu C, Zhong R, Sun X, Shi J. PSME2 identifies immune-hot tumors in breast cancer and associates with well therapeutic response to immunotherapy. *Frontiers in Genetics* 2022; **13**: 1071270.
24. Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. *PLoS One* 2012; **7**(2): e32366.
25. Ferreira CS, Da Silva AT, Brustolini OJB, et al. Immune and vascular modulation by HERVs: the role of CXCR1 and IL18RAP in dengue severity progression. *Frontiers in Immunology* 2025; **16**: 1557588.
26. Buijsers B, Garishah FM, Riswari SF, et al. Increased Plasma Heparanase Activity and Endothelial Glycocalyx Degradation in Dengue Patients Is Associated With Plasma Leakage. *Front Immunol* 2021; **12**: 759570.
27. Srivastava S, Chaudhary N, Dhembla C, Sundd M, Gupta S, Patel AK. STAT3 inhibition mediated upregulation of multiple immune response pathways in dengue infection. *Virology* 2023; **578**: 81-91.
28. Maheshwari D, Saini K, Singh P, et al. Contrasting behavior between the three human monocyte subsets in dengue pathophysiology. *iScience* 2022; **25**(6): 104384.
29. Moallemi S, Lloyd AR, Rodrigo C. Early biomarkers for prediction of severe manifestations of dengue fever: a systematic review and a meta-analysis. *Scientific Reports* 2023; **13**(1): 17485.
30. Valencia BM, Sigera PC, Weeratunga P, et al. Effect of prior Zika and dengue virus exposure on the severity of a subsequent dengue infection in adults. *Scientific Reports* 2022; **12**(1): 17225.

Figures

Figure 1. Comparison groups in the study

Figure 2. Study design and workflow showing sample classification, pooling, and dual-platform proteomic analysis. PL: plasma leakage, PD+: primary dengue, PD-: secondary dengue, SD*: severe dengue (with either compensated or uncompensated shock).

Figure 1. **Differential protein expression in febrile-phase plasma from dengue patients who subsequently developed plasma leakage (POS) versus those who did not (NEG).** Proteins are identified by their UniProt ID in all panels. **(A)** Volcano plot showing differentially expressed proteins detected by LC-MS/MS (log□ fold change ≥ 1, $p \leq 0.05$). A total of 107 proteins were significantly differentially expressed, including 87 upregulated (red) and 20 downregulated (blue).
(B) Volcano plot of SomaScan data (log□ fold change ≥ 0.2, $p \leq 0.05$), identifying 3,181 DEPs: 1,634 upregulated and 1,547 downregulated proteins. Selected annotated proteins are highlighted based on statistical significance and fold change. **(C)** Heatmap showing proteins consistently detected in all biological samples (including technical replicates) of one group (PL+ or PL–) but absent in the other. (Y-axis displays UniProt IDs, corresponding to the following proteins: S100P (P25815), Beta-enolase (P13929), S100-A7A (Q86SG5), Pregnancy-specific beta-1-glycoprotein 9 (Q00887), Small ribosomal subunit protein uS9 (P62249), Crk-like protein (P46109), Platelet-derived growth factor receptor alpha (P16234), Semenogelin-1 (P04279), and a protein similar to Dimethylglycine dehydrogenase (B4DV21).) Each column represents a technical replicate (TR1, TR2) of a biological sample; "POS" indicates PL+ samples and "NEG" indicates PL– samples. The number after POS or NEG shows the sample stratification by prior dengue exposure (POS1 – primary dengue with plasma leakage, POS2 – secondary dengue with plasma leakage, POS3 – severe dengue; NEG1 – primary dengue without plasma leakage, and NEG2 – secondary dengue without plasma leakage). Orange cells represent protein presence; white cells indicate absence. Two proteins (P25815, P13929) were uniquely detected in PL– samples, while seven proteins were uniquely present in PL+ samples.

Figure 2. Enrichment analysis of differentially expressed proteins in plasma leakage. (A) Bar graph of enriched terms across upregulated proteins in plasma leakage. (B) Bar graph of enriched terms across downregulated proteins in plasma leakage with only the first four terms reaching statistical significance after multiple testing correction ($q < 0.05$).

Figure 5. Protein-protein interaction (PPI) networks of differentially expressed proteins in plasma leakage. A) PPI network of upregulated proteins in the plasma leakage group. B) PPI network of downregulated proteins in the plasma leakage group. PPI networks were constructed from significantly differentially expressed proteins ($\log \square FC \geq 1$ or ≤ -1, $p \leq 0.05$) integrated from both the LC-MS/MS and SomaScan proteomics platform. Densely connected clusters were identified using the MCODE algorithm (Molecular Complex Detection). Nodes represent proteins; edges represent known or predicted interactions. Color-coded modules correspond to enriched biological processes, as detailed in the main text and Tables S9 and S11.

Figure 3. Network bottleneck proteins in plasma leakage. (A) Scatter plot showing the relationship between degree centrality and betweenness centrality for bottleneck proteins. (B) Bar chart ranking the top 15 proteins by betweenness centrality, coloured by functional category. Bottleneck proteins are characterized by high betweenness centrality despite relatively low degree connectivity, positioning them as critical bridges between functional modules.



Comparison Legend:

- Comparison 1: No plasma leakage (PL-) vs plasma leakage (PL+) - across all dengue cases
- Comparison 2: Primary dengue without leakage (PD+PL-) vs primary with leakage (PD+PL+)
- Comparison 3: Secondary dengue without leakage (PD-PL-) vs secondary with leakage (PD-PL+)
- Comparison 4: Severe dengue (SD) vs non-severe dengue (all other groups)
- Comparison 5: Severe dengue vs. non-severe dengue in secondary dengue (SD vs. PD-PL+)

Important: Severe dengue (SD) is a subset of plasma leakage cases (PL+)
Non-severe dengue includes all other dengue groups (PD+PL-, PD-PL-, PD+PL+, PD-PL+)


278 plasma samples
50 Febrile non-dengue illnesses
222 Dengue
6 Healthy control
50 PD-PL-
50 PD-PL+
50 PD+PL-
50 PD+PL+
22 SD
Pools
Age and gender matched
50 samples per group except for SD*=22, and HC=6
High abundance depletion
LC-MS/MS
Aptamer-based proteomics
SomaScan
Differential expression analysis
Pathway enrichment analysis
Cross-platform validation


Red = UP in POS, Blue = UP in NEG | Thresholds: P < 0.05, |log2FC| > 1
X5D8S1
P09104
P21291
Q12906
P13224
O60235
P62805
B2RMS9
O43175
V9HW63
3
2
1
0
−log10(P−value)
−2.5
0.0
2.5
5.0
7.5
Log2 Fold Change
Significance
Not Significant
UP in NEG
UP in POS
NA


Red = UP in POS, Blue = UP in NEG | Thresholds: P < 0.05, |log2FC| > 0.2
Q7L513
Q495W5
Q96PL2
Q6ZMM2
Q9BQS7
P27701
Q96CJ1
Q16690
O00488
Q9BSE5
P38398
P08962
Q92963
Q14103
P14921
8
6
4
2
0
−4
0
4
−log10(P−value)
Log2 Fold Change
Significance
Not Significant
UP in NEG
UP in POS


P25815
P13929
Q86SG5
Q00887
P62249
P46109
P16234
P04279
B4DV21
UniProt ID
Unique to NEG
Unique to POS
NEG1_TR1
NEG1_TR2
NEG2_TR1
NEG2_TR2
POS1_TR1
POS1_TR2
POS2_TR1
POS2_TR2
POS3_TR1
POS3_TR2
Sample
Present
Absent
Present


GO:0019752: carboxylic acid metabolic process
GO:0044248: cellular catabolic process
hsa04151: PI3K-Akt signaling pathway
R-HSA-109582: Hemostasis
CORUM:192: PA28-20S proteasome
R-HSA-1280215: Cytokine Signaling in Immune system
GO:0007599: hemostasis
M5885: NABA MATRISOME ASSOCIATED
WP3925: Amino acid metabolism
hsa04630: JAK-STAT signaling pathway
GO:0009410: response to xenobiotic stimulus
GO:1901615: organic hydroxy compound metabolic process
R-HSA-196854: Metabolism of vitamins and cofactors
M36: PID IL27 PATHWAY
hsa00280: Valine, leucine and isoleucine degradation
WP4495: IL10 anti inflammatory signaling
R-HSA-6798695: Neutrophil degranulation
GO:0006979: response to oxidative stress
GO:0019362: pyridine nucleotide metabolic process
GO:0170043: non-proteinogenic amino acid biosynthetic process
0
2
4
6
8
10
12
14
16
-log10(P)


GO:0031401: positive regulation of protein modification process
GO:2001233: regulation of apoptotic signaling pathway
GO:0014002: astrocyte development
R-HSA-1280218: Adaptive Immune System
R-HSA-5668599: RHO GTPases Activate NADPH Oxidases
GO:0007169: cell surface receptor protein tyrosine kinase signaling pathway
GO:0009611: response to wounding
GO:0043122: regulation of canonical NF-kappaB signal transduction
GO:0030162: regulation of proteolysis
GO:0008544: epidermis development
GO:0000165: MAPK cascade
GO:0050731: positive regulation of peptidyl-tyrosine phosphorylation
WP3888: VEGFA VEGFR2 signaling
R-HSA-9006934: Signaling by Receptor Tyrosine Kinases
GO:0002921: negative regulation of humoral immune response
GO:0050808: synapse organization
M50: PID PTP1B PATHWAY
R-HSA-111465: Apoptotic cleavage of cellular proteins
M256: PID TAP63 PATHWAY
GO:0050865: regulation of cell activation
0
1
2
3
4
5
6
-log10(P)



Color	MCODE	GO	Description	Log10(P)
	MCODE_1	CORUM:192	PA28-20S proteasome	-17.5
	MCODE_1	CORUM:193	PA700-20S-PA28 complex	-15.1
	MCODE_1	hsa03050	Proteasome	-14.4
	MCODE_2	R-HSA-3371511	HSF1 activation	-8.1
	MCODE_2	CORUM:5199	Kinase maturation complex 1	-7.7
	MCODE_2	R-HSA-2262752	Cellular responses to stress	-7.2
	MCODE_3	hsa00260	Glycine, serine and threonine metabolism	-6.7
	MCODE_3	GO:0006575	modified amino acid metabolic process	-4.8
	MCODE_3	GO:0044248	cellular catabolic process	-4.1
	MCODE_4	hsa04630	JAK-STAT signaling pathway	-14.9
	MCODE_4	WP4495	IL10 anti inflammatory signaling	-12.0
	MCODE_4	WP5083	Neuroinflammation and glutamatergic signaling	-10.0
	MCODE_5	GO:0019752	carboxylic acid metabolic process	-12.7
	MCODE_5	GO:0032787	monocarboxylic acid metabolic process	-9.1
	MCODE_5	WP3925	Amino acid metabolism	-8.3
	MCODE_6	R-HSA-975634	Retinoid metabolism and transport	-8.1
	MCODE_6	R-HSA-6806667	Metabolism of fat-soluble vitamins	-8.0
	MCODE_6	R-HSA-2187338	Visual phototransduction	-7.0
	MCODE_7	R-HSA-202733	Cell surface interactions at the vascular wall	-7.3
	MCODE_7	GO:0007565	female pregnancy	-6.7
	MCODE_7	GO:0044703	multi-organism reproductive process	-6.6









Color	MCODE	GO	Description	Log10(P)
	MCODE_2	R-HSA-6799990	Metal sequestration by antimicrobial proteins	-10.8
	MCODE_2	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	-9.1
	MCODE_2	GO:0050832	defense response to fungus	-7.5
	MCODE_3	hsa04512	ECM-receptor interaction	-7.6
	MCODE_3	WP306	Focal adhesion	-6.6
	MCODE_3	hsa04510	Focal adhesion	-6.5


1e-3
8e-4
6e-4
4e-4
2e-4
0
Betweenness Centrality
0
1
2
3
4
5
6
7
8
Degree Centrality
Bottleneck Proteins


Betweenness Centrality
1e-3
1e-3
8e-4
8e-4
6e-4
6e-4
4e-4
4e-4
2e-4
0
RTCA
ITIH1
TLR6
FDPS
HAO1
H4C1
POLR3E
OGG1
NRL
AGA
PRDX5
MUSK
NOVA1
LAMC1
PFN4
Functional Categories:
RNA Processing
Protease Inhibitor
Immune Signaling
Metabolism
DNA Repair
Transcription
Histone/Chromatin
Transcription Factor
Antioxidant